yingweiwo

Suntinorexton

Cat No.:V69997 Purity: ≥98%
Suntinorexton, a heterocyclic compound, is an orexin type 2 receptor agonist.
Suntinorexton
Suntinorexton Chemical Structure CAS No.: 2274802-89-8
Product category: OX Receptor
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
10mg
25mg
50mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Product Description
Suntinorexton, a heterocyclic compound, is an orexin type 2 receptor agonist. For more details, check and find the patent document WO2019027058A1.
Suntinorexton (TAK-861) is an orally active and selective OX2R agonist with an EC50 of 2.5 nM. It is a heterocyclic compound that acts as an orexin type 2 receptor agonist. With a molecular weight of 466.54 and formula C23H28F2N2O4S, this compound ameliorates narcolepsy-like phenotypes. It is intended for research purposes only and is not for human therapeutic use.
Biological Activity I Assay Protocols (From Reference)
Targets
orexin type 2 receptor[1]
Suntinorexton targets the orexin type 2 receptor (OX2R) as a selective and orally active agonist. It has an EC50 of 2.5 nM for OX2R. Orexin receptors are involved in the regulation of wakefulness, sleep-wake transitions, and appetite. By activating OX2R, Suntinorexton promotes wake-promoting signaling pathways in the central nervous system. Its oral activity and high potency make it a valuable tool for studying the specific roles of OX2R in sleep-wake regulation and for developing treatments for sleep disorders such as narcolepsy.
ln Vitro
In vitro studies demonstrate that Suntinorexton (TAK-861) is an orally active and selective OX2R agonist with an EC50 of 2.5 nM. It activates OX2R with high potency and selectivity, promoting wake-promoting signaling pathways. The compound's oral activity and high potency make it a valuable tool for studying orexin receptor pharmacology and for developing small-molecule treatments for sleep disorders. Detailed in vitro characterization data, including receptor binding and functional assays, are available in the primary literature.
ln Vivo
In vivo studies of Suntinorexton have demonstrated its efficacy in ameliorating narcolepsy-like phenotypes. As an orally active OX2R agonist, it promotes wake-promoting signaling pathways in the central nervous system. Specific in vivo efficacy data, including effects on sleep-wake parameters and narcolepsy symptoms, are available in the primary literature. The compound's oral bioavailability supports its use in in vivo studies. Further research is ongoing to characterize its full therapeutic potential for narcolepsy and other sleep disorders.
Enzyme Assay
For OX2R binding assays, membrane preparations from cells expressing recombinant OX2R are incubated with radiolabeled ligands and varying concentrations of Suntinorexton. Non-specific binding is determined using excess unlabeled reference compounds. Following incubation at appropriate temperature (typically 25°C for 60-90 minutes), bound and free radioligands are separated by rapid filtration through glass fiber filters. Filters are washed and radioactivity counted by liquid scintillation. IC50 or Ki values are calculated from competition curves. For functional assays, receptor activation is measured by calcium flux or IP3 accumulation assays.
Cell Assay
For in vitro cellular assays, cell lines expressing OX2R (e.g., CHO or HEK293 cells) are cultured in appropriate media under standard conditions (37°C, 5% CO2). Suntinorexton is dissolved in DMSO and diluted in culture medium to desired concentrations. Cells are treated with compound for specified durations. Receptor activation is assessed by measuring intracellular calcium flux using fluorescent indicators or by measuring downstream signaling pathways. Cell viability and cytotoxicity can be assessed using standard assays. Each concentration is tested in replicate wells with vehicle controls and positive controls (e.g., orexin-A).
Animal Protocol
For in vivo animal studies, Suntinorexton is typically administered orally (by gavage) due to its oral activity. In narcolepsy models, animals are treated with compound and sleep-wake parameters are monitored using EEG/EMG recordings. Narcolepsy-like phenotypes, including cataplexy and sleep fragmentation, are assessed. For pharmacokinetic studies, blood and brain tissue samples are collected at predetermined time points post-administration, and drug concentrations are quantified by LC-MS/MS. All procedures must follow institutional animal care and use committee guidelines.
ADME/Pharmacokinetics
Pharmacokinetic properties of Suntinorexton indicate it is orally active. The compound has a molecular weight of 466.54 and formula C23H28F2N2O4S. CAS number: 2274802-89-8. Storage: typically at -20°C for powder; in solvent at -80°C. Solubility: soluble in DMSO and other organic solvents. As a small-molecule OX2R agonist, it is expected to have favorable oral bioavailability. Specific pharmacokinetic parameters such as half-life, clearance, and bioavailability are reported in the primary literature.
Toxicity/Toxicokinetics
According to available safety information, Suntinorexton is intended for research purposes only and is not for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment (gloves, lab coat, safety goggles). The compound should be handled in a well-ventilated area. Avoid dust formation and inhalation. In case of skin contact, wash with plenty of soap and water. In case of eye contact, rinse cautiously with water for several minutes. No clinical toxicity data are available.
References

[1]. Heterocyclic compound and use thereof. WO2019027058A1.

Additional Infomation
Suntinorexton (TAK-861) is an orally active and selective OX2R agonist with an EC50 of 2.5 nM. It is a heterocyclic compound that ameliorates narcolepsy-like phenotypes. It has a molecular weight of 466.54 and formula C23H28F2N2O4S. It is for research use only with no regulatory approvals reported.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C23H28F2N2O4S
Molecular Weight
466.54
Exact Mass
466.173
CAS #
2274802-89-8
Related CAS #
(R,R)-Suntinorexton
PubChem CID
137460941
Appearance
White to off-white solid powder
LogP
3.2
tPSA
95.1
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
7
Rotatable Bond Count
7
Heavy Atom Count
32
Complexity
758
Defined Atom Stereocenter Count
2
SMILES
C(S(N[C@H]1CCN(C(=O)C(O)(C)C)[C@H]1CC1C=CC=C(C2=CC=CC(F)=C2)C=1F)(=O)=O)C
InChi Key
MQDUVMBBJZLFHF-PMACEKPBSA-N
InChi Code
InChI=1S/C23H28F2N2O4S/c1-4-32(30,31)26-19-11-12-27(22(28)23(2,3)29)20(19)14-16-8-6-10-18(21(16)25)15-7-5-9-17(24)13-15/h5-10,13,19-20,26,29H,4,11-12,14H2,1-3H3/t19-,20-/m0/s1
Chemical Name
N-[(2S,3S)-2-[[2-fluoro-3-(3-fluorophenyl)phenyl]methyl]-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~200 mg/mL (~428.7 mM; with ultrasonication)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 5 mg/mL (10.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 5 mg/mL (10.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.1434 mL 10.7172 mL 21.4344 mL
5 mM 0.4287 mL 2.1434 mL 4.2869 mL
10 mM 0.2143 mL 1.0717 mL 2.1434 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration: mg/mL;

Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Contact Us